Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
Miranda
Phillippa J
PJ
Diabetes Division, University of Texas Health Science Center, San Antonio, Tex, USA.
DeFronzo
Ralph A
RA
Califf
Robert M
RM
Guyton
John R
JR
D001161:Arteriosclerosis / Q000000981:diagnostic imaging / Q000209:etiology* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D004730:Endothelium, Vascular / Q000503:physiopathology; D017048:Health Care Costs; D006801:Humans; D006973:Hypertension / Q000150:complications; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008019:Life Style; D008074:Lipoproteins / Q000502:physiology; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000628:therapy*; D008687:Metformin / Q000627:therapeutic use; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists*; D011859:Radiography; D012307:Risk Factors; D014463:Ultrasonography
D007004:Hypoglycemic Agents; D008074:Lipoproteins; D047492:Peroxisome Proliferator-Activated Receptors; D008687:Metformin